Retapamulin Ointment – Uses, Dosage, Side Effects Retapamulin Ointment /Retapamulin is a topical antibiotic developed by GlaxoSmithKline. It was approved by the United States Food and Drug Administration in April 2007 for the treatment of bacterial skin infections such as impetigo. It is marketed as an ointment under the name brand Altabax. Retapamulin, marketed by GlaxoSmithKline as the ointment Altabax, is an antibiotic for skin infections like impetigo. It was approved by the FDA in April 2007. Retapamulin is a Pleuromutilin Antibacterial. The chemical classification of retapamulin is pleuromutilin. Mechanism of Action of Retapamulin Retapamulin is a bacterial protein synthesis inhibitor belonging to a class of compounds called pleuromutilins. These compounds inhibit the initiation of protein synthesis by binding to a specific site on the 50S subunit of bacterial ribosome (domain V of 23S rRNA). This binding site involves ribosomal protein L3 and is in the region of the ribosomal P site and peptidyl transferase center. By virtue of binding to this site, pleuromutilins inhibit peptidyl transfer, block P-site interactions, and prevent the normal formation of active 50S ribosomal subunits. Indications of Retapamulin For use in adults and pediatric patients aged 9 months and older for the topical treatment of impetigo (up to 100 cm2 in total area in adults or 2% total body surface area in pediatric patients aged 9 months or older) due to Staphylococcus aureus (methicillin-susceptible isolates only) or Streptococcus pyogenes. Short term treatment of the following superficial skin infections in adults, adolescents, infants, and children. Impetigo. Infected small lacerations, abrasions, or sutured wounds. regarding the clinical activity of retapamulin against different types of Staphylococcus aureus. Consideration should be given to official guidance on the appropriate use of antibacterial medicinal products. Short term treatment of the following superficial skin infections, small lacerations, abrasions or sutured wounds. Consideration should be given to official guidance on the appropriate use of antibacterial agents. Staphylococcal impetigo Streptococcal impetigo Acne You Might Also Read Sirolimus - Uses, Dosage, Side Effects, Interaction Dosage of Retapamulin Strengths: 1% Impetigo Apply a thin layer to the affected area (up to 100 cm2 in total area) twice a day for 5 days Pediatric Dose for Impetigo Apply a thin layer to the affected area (up to 2% total body surface area) twice a day for 5 days Side Effects of Retapamulin Most Common Burning, itching, redness, skin rash, swelling, or soreness at the site Burning, crusting, dryness, flaking of skin Skin rash, encrusted, scaly, and oozing Signs of a serious allergic reaction (e.g., abdominal cramps, difficulty breathing, nausea and vomiting, or swelling of the face and throat) Diarrhea (watery and severe; may also be bloody) Common Redness of the skin itching, scaling, severe redness, soreness, swelling of the skin pain at the site of application unusually warm skin Blistering, crusting, irritation, itching, or reddening of the skin canker sores cracked, dry, scaly skin pain, swelling, tenderness, warmth on the skin sores, ulcers, or white spots on the lips or tongue or inside the mouth Rare Abdominal or stomach tenderness cough difficulty with swallowing dizziness fast heartbeat fever hives or welts, itching, or skin rash large, hive-like swelling on the face, eyelids, lips, tongue, throat, hands, legs, feet, or sex organs puffiness or swelling of the eyelids or around the eyes, face, lips, or tongue redness of the skin severe abdominal or stomach cramps and pain tightness in the chest unusual tiredness or weakness watery and severe diarrhea, which may also be bloody Drug Interactions of Retapamulin Ointment Retapamulin may interact with following drugs, supplements & may change the efficacy of drugs amiodarone amprenavir aprepitant atazanavir bicalutamide bromocriptine ceritinib chloramphenicol cimetidine ciprofloxacin clarithromycin clotrimazole conivaptan cyclosporine danazol darunavir dasatinib delavirdine dihydroergotamine diltiazem erythromycin fedratinib fluconazole fluvoxamine fosamprenavir fosaprepitant fostamatinib imatinib indinavir isavuconazonium isoniazid itraconazole ketoconazole lapatinib miconazole nifedipine posaconazole ribociclib telithromycin troleandomycin verapamil voriconazole zafirlukast You Might Also Read Asparlas - Uses, Dosage, Side Effects, InteractionPregnancy Category Of Retapamulin Ointment Pregnancy The safety of this medication for the treatment of infections during pregnancy is unknown. If you are or may be pregnant, talk to your doctor about the benefits and risks of using retapamulin. Lactation If you are breast-feeding, talk to your doctor about the benefits and risks of using this medication. If you are using this medication to treat a cracked nipple, your doctor may advise you to use a breast pump to pump the milk from the affected breast while you are using this medicine. References DrugBank https://www.drugbank.ca/legal/terms_of_use http://www.drugbank.ca/drugs/DB01256 http://www.drugbank.ca/drugs/DB01256 http://www.drugbank.ca/drugs/DB01256 https://www.drugs.com/drug-interactions/retapamulin-topical.html https://www.drugs.com/mtm/retapamulin-topical.html Human Metabolome Database (HMDB) http://www.hmdb.ca/citing http://www.hmdb.ca/metabolites/HMDB0015386 ClinicalTrials.gov https://clinicaltrials.gov/ct2/about-site/terms-conditions#Use https://clinicaltrials.gov/ DailyMed https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=RETAPAMULIN FDA Pharm Classes https://www.fda.gov/about-fda/about-website/website-policies#linking https://dailymed.nlm.nih.gov/dailymed/browse-drug-classes.cfm https://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/ucm162549.htm EU Community Register of Medicinal Products https://ec.europa.eu/health/documents/community-register/html/h390.htm European Medicines Agency (EMA) https://www.ema.europa.eu/en/medicines/human/EPAR/altargo EU Clinical Trials Register https://www.clinicaltrialsregister.eu/ WHO ATC https://www.whocc.no/copyright_disclaimer/ https://www.whocc.no/atc/ https://www.whocc.no/atc_ddd_index/ European Chemicals Agency (ECHA) https://echa.europa.eu/web/guest/legal-notice https://echa.europa.eu/information-on-chemicals/cl-inventory-database/-/discli/details/171995 FDA Orange Book https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/Drugs/InformationOnDrugs/ucm129662.htm FDA/SPL Indexing Data https://www.fda.gov/about-fda/about-website/website-policies#linking https://www.fda.gov/ForIndustry/DataStandards/SubstanceRegistrationSystem-UniqueIngredientIdentifierUNII/ Protein Data Bank in Europe (PDBe) http://www.ebi.ac.uk/pdbe-srv/pdbechem/chemicalCompound/show/G34 https://pubchem.ncbi.nlm.nih.gov/compound/Retapamulin Wikipedia https://en.wikipedia.org/wiki/Retapamulin https://pubchem.ncbi.nlm.nih.gov MeSH https://www.ncbi.nlm.nih.gov/mesh/67508887 http://www.nlm.nih.gov/mesh/meshhome.html https://www.ncbi.nlm.nih.gov/mesh/68000900 Show More